Twist Bioscience (NASDAQ:TWST) Trading Up 9.5% - What's Next?

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) shares traded up 9.5% during mid-day trading on Wednesday . The company traded as high as $46.91 and last traded at $46.81. 123,251 shares traded hands during trading, a decline of 80% from the average session volume of 617,160 shares. The stock had previously closed at $42.75.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target on the stock. Scotiabank raised their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a research note on Tuesday, November 19th. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Finally, Robert W. Baird boosted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $51.90.

Twist Bioscience Stock Up 6.4 %

The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of -12.63 and a beta of 1.85. The firm has a 50 day moving average price of $46.42 and a two-hundred day moving average price of $46.33.

Insiders Place Their Bets

In other news, COO Patrick John Finn sold 2,261 shares of the business's stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $43.09, for a total value of $97,426.49. Following the completion of the sale, the chief operating officer now owns 159,483 shares of the company's stock, valued at approximately $6,872,122.47. The trade was a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emily M. Leproust sold 14,334 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total transaction of $639,296.40. Following the transaction, the chief executive officer now directly owns 589,552 shares in the company, valued at $26,294,019.20. The trade was a 2.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 89,640 shares of company stock worth $4,123,772 in the last three months. 3.92% of the stock is owned by insiders.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Signaturefd LLC grew its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after acquiring an additional 306 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Twist Bioscience by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock worth $457,000 after purchasing an additional 312 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Twist Bioscience by 2.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company's stock worth $734,000 after purchasing an additional 363 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after purchasing an additional 381 shares during the last quarter. Finally, D.A. Davidson & CO. raised its holdings in shares of Twist Bioscience by 3.5% during the third quarter. D.A. Davidson & CO. now owns 19,618 shares of the company's stock worth $886,000 after purchasing an additional 664 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.